Objective: Hormonal contraceptives are contraindicated in pregnancy. However, some women may become pregnantwhile using contraceptives to prevent pregnancy. In addition, these hormones may be used for abnormal uterine bleeding orsecondary amenorrhea. In the present study, we evaluated the fetal outcomes of pregnant women who were inadvertentlyexposed to hormonal contraceptives during anytime in pregnancy. The aim of the present study was to expand the dataabout contraceptives with regard to their potential teratogenic effects.Materials and Methods: We collected data of pregnant women who were admitted to the Teratology Information Service(TIS) between 2014 and 2018 with hormonal contraception exposure during pregnancy. Data about medications, exposureto other agents, and comorbidities were documented. We analyzed the exposed drugs with respect to their potential teratogenic effects. Follow-up was conducted with women after delivery to determine whether any major or minor congenitalmalformations or adverse neurodevelopmental effects occurred in infants.Results: A total of 25 pregnant women who were admitted to the TIS for inadvertent use of hormonal contraception duringpregnancy were included in the study. After delivery, we found that one female baby, who was exposed to medroxyprogesterone acetate in utero, had exitus postnatally in the first week of life. Three infants with maternal exposure to medroxyprogesterone acetate, dydrogesterone, estradiol valerate+norgestrel, and ethinyl estradiol+gestodene were born preterm.Among the three infants, two with maternal exposure to medroxyprogesterone acetate and ethinyl estradiol+gestodene hadlow birth weight. On the other hand, we found that 75% of the infants delivered were female.Conclusion: Contraceptive hormones presented no major teratogenic effects. However, avoidance of hormonal exposureand discontinuation whenever possible during pregnancy are suggested.